Nothing Special   »   [go: up one dir, main page]

NO20022330L - Analgesiske preparater inneholdende buprenorfin - Google Patents

Analgesiske preparater inneholdende buprenorfin

Info

Publication number
NO20022330L
NO20022330L NO20022330A NO20022330A NO20022330L NO 20022330 L NO20022330 L NO 20022330L NO 20022330 A NO20022330 A NO 20022330A NO 20022330 A NO20022330 A NO 20022330A NO 20022330 L NO20022330 L NO 20022330L
Authority
NO
Norway
Prior art keywords
preparations containing
containing buprenorphine
analgesic preparations
analgesic
buprenorphine
Prior art date
Application number
NO20022330A
Other languages
English (en)
Other versions
NO20022330D0 (no
NO321965B1 (no
Inventor
Christopher Bourne Chapleo
Nicolas Calvert Varey
Keith Mccormack
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of NO20022330D0 publication Critical patent/NO20022330D0/no
Publication of NO20022330L publication Critical patent/NO20022330L/no
Publication of NO321965B1 publication Critical patent/NO321965B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20022330A 1999-11-19 2002-05-15 Analgesiske preparater inneholdende buprenorfin NO321965B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14
PCT/GB2000/004372 WO2001035942A2 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine

Publications (3)

Publication Number Publication Date
NO20022330D0 NO20022330D0 (no) 2002-05-15
NO20022330L true NO20022330L (no) 2002-07-04
NO321965B1 NO321965B1 (no) 2006-07-31

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022330A NO321965B1 (no) 1999-11-19 2002-05-15 Analgesiske preparater inneholdende buprenorfin

Country Status (31)

Country Link
US (4) US6995169B2 (no)
EP (1) EP1242087B1 (no)
JP (1) JP4745576B2 (no)
KR (1) KR100726699B1 (no)
CN (1) CN100431543C (no)
AR (1) AR031682A1 (no)
AT (1) ATE262335T1 (no)
AU (1) AU777259B2 (no)
BR (1) BR0015580A (no)
CA (1) CA2392013C (no)
CO (1) CO5261517A1 (no)
CZ (1) CZ303160B6 (no)
DE (1) DE60009346T2 (no)
DK (1) DK1242087T3 (no)
ES (1) ES2214334T3 (no)
GB (1) GB2356348B (no)
HK (1) HK1055389A1 (no)
HU (1) HU229565B1 (no)
IL (2) IL149580A0 (no)
MX (1) MXPA02004978A (no)
NO (1) NO321965B1 (no)
NZ (1) NZ519023A (no)
PL (1) PL199727B1 (no)
PT (1) PT1242087E (no)
RO (1) RO121174B1 (no)
RU (1) RU2255737C2 (no)
SI (1) SI21025B (no)
SK (1) SK286888B6 (no)
TR (1) TR200400653T4 (no)
TW (1) TW550070B (no)
WO (1) WO2001035942A2 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
AU2006323048B2 (en) * 2005-11-22 2013-07-04 Nalpropion Pharmaceuticals Llc Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US8093261B2 (en) 2006-10-24 2012-01-10 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447015A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
ES2572157T3 (es) * 2007-09-03 2016-05-30 Nanotherapeutics Inc Composiciones en forma de partículas para la administración de fármacos poco solubles
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
LT2826467T (lt) 2010-12-22 2017-09-25 Purdue Pharma L.P. Padidinto saugumo kontroliuojamo atpalaidavimo vaisto forma
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EA029507B1 (ru) 2011-09-19 2018-04-30 Орексо Аб Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2015038327A1 (en) 2013-09-10 2015-03-19 Insys Pharma, Inc. Sublingual buprenorphine spray
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CN106456634A (zh) 2014-04-22 2017-02-22 大塚制药株式会社 布雷帕唑和纳美芬的组合及其用于治疗物质有关的病症的用途
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
AU2021217164A1 (en) * 2020-02-05 2022-08-25 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
JP2004501094A (ja) * 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法

Also Published As

Publication number Publication date
CZ303160B6 (cs) 2012-05-09
WO2001035942A3 (en) 2002-06-13
JP4745576B2 (ja) 2011-08-10
AR031682A1 (es) 2003-10-01
BR0015580A (pt) 2002-07-09
ATE262335T1 (de) 2004-04-15
SK286888B6 (sk) 2009-07-06
TW550070B (en) 2003-09-01
US20060069113A1 (en) 2006-03-30
HK1055389A1 (en) 2004-01-09
US7402591B2 (en) 2008-07-22
RO121174B1 (ro) 2007-01-30
EP1242087A2 (en) 2002-09-25
IL149580A (en) 2007-05-15
GB0028088D0 (en) 2001-01-03
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
WO2001035942A9 (en) 2002-11-28
US6995169B2 (en) 2006-02-07
TR200400653T4 (tr) 2004-04-21
PT1242087E (pt) 2004-06-30
DK1242087T3 (da) 2004-07-19
RU2255737C2 (ru) 2005-07-10
NO20022330D0 (no) 2002-05-15
DE60009346D1 (de) 2004-04-29
CN1413110A (zh) 2003-04-23
CA2392013A1 (en) 2001-05-25
RU2002116361A (ru) 2004-01-27
CO5261517A1 (es) 2003-03-31
CA2392013C (en) 2009-08-11
US20060058333A1 (en) 2006-03-16
NZ519023A (en) 2004-11-26
GB2356348B (en) 2002-02-06
AU1529701A (en) 2001-05-30
HU229565B1 (hu) 2014-02-28
EP1242087B1 (en) 2004-03-24
ES2214334T3 (es) 2004-09-16
AU777259B2 (en) 2004-10-07
KR100726699B1 (ko) 2007-06-13
CN100431543C (zh) 2008-11-12
JP2003514013A (ja) 2003-04-15
MXPA02004978A (es) 2003-01-28
IL149580A0 (en) 2002-11-10
WO2001035942A2 (en) 2001-05-25
HUP0203588A3 (en) 2005-01-28
GB2356348A (en) 2001-05-23
KR20020058022A (ko) 2002-07-12
PL355330A1 (en) 2004-04-19
SI21025B (sl) 2008-04-30
NO321965B1 (no) 2006-07-31
PL199727B1 (pl) 2008-10-31
DE60009346T2 (de) 2005-02-10
HUP0203588A2 (hu) 2003-03-28
SK8762002A3 (en) 2002-12-03
US20060058332A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
NO20022330L (no) Analgesiske preparater inneholdende buprenorfin
IS6040A (is) Valdekoxib efnablöndur
DE60038698D1 (de) Hydrogel-gesteuerte dosierungsform
DE60020343D1 (de) Cilostazol enthaltende zubereitung
EE200200038A (et) Konservitud farmatseutilised preparaadid
NO20071303L (no) Farmasoytiske preparater
FI991485A (fi) Uusi farmaseuttinen koostumus
DK1210113T3 (da) Kombinerede vaccinepræparater
EP1329217A4 (en) Solid preparations
ATE485823T1 (de) Kombinationspräparate enthaltend (e)-7-ä4-(4- fluorophenyl)-6-isopropyl-2-
ATE332132T1 (de) Verbesserte arzneizubereitungen enthaltend ritonavir
NO990431D0 (no) Golfk°llehode
NO20022606D0 (no) Farmasöytiske kombinasjoner
NO20014926D0 (no) Farmasöytiske forbindelser
ATE298576T1 (de) Arzneizubereitungen
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
EE200100697A (et) Farmatseutiline kompleks
AR025867A1 (es) Formulacion portasdora farmaceutica
ATE237309T1 (de) Arzneizubereitungen
NO20004816D0 (no) Ny farmasøytisk formulering
DE50009295D1 (de) Vernetzerfreie zubereitungen
DE69907862D1 (de) Dreirolleneinführung
DE50008261D1 (de) Retardierte darreichungsform enthaltend tramadolsaccharinat
ATE252549T1 (de) Aminobutyronitril mischung
ATA36099A (de) Stoffgemisch

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: RB PHARMACEUTICALS LTD

Free format text: NEW ADDRESS: 102-105 BATH ROAD, GB-SL13UH SLOUGH

MM1K Lapsed by not paying the annual fees